Skip to main content
Premium Trial:

Request an Annual Quote

Andrew Serafini, Pat Frain

Premium
Fenwick & West, a technology and life sciences law firm with offices in Seattle, Silicon Valley, San Francisco, and Boise, Idaho, said this week that Andrew Serafini has been named as a partner in its firm-wide intellectual property group.
 
Serafini is based in Fenwick & West’s Seattle office, where his practice focuses on IP counseling for life sciences companies, with particular expertise in the areas of immunology, molecular biology, molecular genetics, genomics, proteomics and protein chemistry, pharmaceuticals, and medical diagnostics.
 
Prior to joining Fenwick & West, Serafini was a partner at Woodcock Washburn in Seattle. He received a JD in 1998 from the University of California, Hastings College of Law. He also received a PhD in immunology in 1994 from Stanford University School of Medicine.
 

 
Pat Frain has been elected chair of ProTon Europe, a pan-European network of knowledge transfer offices, national knowledge transfer associations, and companies affiliated to universities and other public research organizations.
 
Frain is currently director of NovaUCD, the innovation and technology transfer center at University College Dublin.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.